Unum Therapeutics

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, will participate in a fireside chat during the 11th Annual SVB Leerink Global Healthcare Conference, taking place virtually February 14 – 18, 2022.

Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its name change to Cogent Biosciences, Inc. ("Cogent"). Beginning on October...

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress

Is  (UMRX) Outperforming Other Medical Stocks This Year?

Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?

CAMBRIDGE, Mass., Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO

CAMBRIDGE, Mass., Aug. 11, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Kopin

Novavax

QuidelOrtho Corp

Veritone

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside

Is Unum Therapeutics (UMRX) Outperforming Other Medical Stocks This Year?

Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.

Unum Therapeutics Inc. (UMRX) Outpaces Stock Market Gains: What You Should Know

PHILADELPHIA, July 21, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Unum Therapeutics Inc. (NASDAQ: UMRX) ("Unum" or the "Company") on behalf of the Company's investors.

Kaskela Law LLC Announces Investigation of Unum Therapeutics Inc. and Encourages Long-Term Investors to Contact the Firm - UMRX

Maxim Integrated Products

Thermo Fisher Scientific

Top Ranked Momentum Stocks to Buy for July 17th

BrightSphere Investment Group

Nautilus

Pacira Pharmaceuticals

Top Ranked Momentum Stocks to Buy for July 10th

As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).

Unum Therapeutics Inc. (UMRX) Shares March Higher, Can It Continue?

Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Unum Therapeutics (UMRX) Catches Eye: Stock Jumps 8.6%

Unum Therapeutics (UMRX) stock is on the rise Tuesday following the acquisition of private biotechnology company Kiq on Monday.
The post Unum Therapeutics: Why UMRX Stock Is Shooting 7% Higher Today appeared first on InvestorPlace.

Unum Therapeutics: Why UMRX Stock Is Shooting 7% Higher Today

CAMBRIDGE, Mass. and PHILADELPHIA, July 6, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announced it has completed the acquisition of Kiq LLC ("Kiq"), a privately held,...

Unum Therapeutics Inc. Announces Acquisition of Kiq LLC

Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Unum Therapeutics Inc (UMRX) Reports Q1 Loss, Tops Revenue Estimates

During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.

What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 120.00% and 271.07%, respectively, for the quarter ended December 2019.

Unum Therapeutics Inc. (UMRX) Q4 Earnings and Revenues Beat Estimates

CAMBRIDGE, Mass., March  20, 2020  (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to $25 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor.

Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism

Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers

-Cohort 1 enrollment is complete with no dose-limiting toxicities observed-

Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers

-Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL- -Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL-

Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019.

News for Unum Therapeutics Stock (UMRX)